Translational Lifestyle Medicine Approaches to Cardiovascular–Kidney–Metabolic Syndrome

Cardiovascular-Kidney-Metabolic (CKM) syndrome arises from interrelated cardiovascular, renal, and metabolic pathways that require coordinated therapeutic strategies. This narrative review synthesizes recent systematic reviews, meta-analyses, and original studies to evaluate the translational application of lifestyle medicine (LM) for CKM management. Evidence indicates that LM interventions targeting the six pillars of practice (nutrition, physical activity, stress management, sleep, social support, and avoidance of risky substances) can improve blood pressure, lipid profiles, glycemic control, and weight, with benefits that complement or at times rival pharmacotherapy. We outline opportunities at the LM-drug interface, including sodium-glucose cotransporter-2 inhibitors and nutrient-stimulated hormone agents such as GLP-1 and GIP, and highlight the need to test synergy and sequencing with LM. Persistent implementation barriers include prioritization of drug-centric care and limited protocolized delivery; the AHA 5A model and digital health tools, including wearables that enable real-time feedback, provide practical routes for integration. Marginalized populations carry a disproportionate burden of CKM, underscoring the need for equitable, culturally tailored approaches. Sex-specific gaps, particularly in post-menopausal lipid metabolism and insulin sensitivity, point to the promise of genomic and nutraceutical personalization. Future work should use preregistered, adequately powered multimodal trials to establish durable, scalable pathways for CKM care.